Quarterly Technical Reports

2020Q1
Detection of Drugs with Low Market Penetration in the Survey of NonMedical Use of Prescription Drugs Program

2020Q2
Use of Self-Report Data Results in Differential Misclassification and Results in Biased Estimates of Differences Between Specific Opioid Analgesic Products

2020Q3
Suspected Suicidal Exposures involving Prescription Opioids Reported to Poison Centers Decreased following the Emergence of the COVID-19 Pandemic; Abuse Exposures Increased

2020Q4
Accounting for Bias from Repeat Respondents in the Survey of Non-Medical Use of Prescription Drugs Program

2019Q1
Redesign of Survey of Non-Medical Use of Prescription Drugs Program Improves Benchmark Estimates

2019Q2
Multiple Imputation of Missing Data in the Poison Center Program

2019Q3
The Prevalence of Methamphetamine Use is Increasing Among Individuals Entering Medication-Assisted Treatment Programs for Opioid Use Disorders

2019Q4
Prevalence of Illicit Drug Use and Non-Medical Prescription Drug Use among Pregnant Women in the United States

2018Q1
Increases in natural and semi-synthetic opioid deaths coincide with concurrent heroin and illicit fentanyl use

2018Q2
Pediatric Suspected Suicide Exposures Involving Prescription Stimulants Are Increasing Faster than Stimulant Prescriptions

2018Q3
Rates of Abuse for Opioids with Low Dispensing are Overestimated due to Careless Response Patterns on Treatment Center Program Surveys

2018Q4
Matching Poison Center Deaths with Death Certificate Data

2017Q1
Tampering with Prescription Opioids Among Individuals Entering Treatment for Substance Use Disorder

2017Q2
Comparison of Population Rate Trends between the National Vital Statistics System and the RADARS® System Medical Examiner Program

2017Q3
Implications of Declining Poison Center Case Volume on Drug Abuse Trend Monitoring

2017Q4
Prevalence of inhalation and injection use among intentional abuse exposure cases involving methylphenidate in the Poison Center Program

2016Q1
Effect of hydrocodone rescheduling on intentional abuse exposures reported to poison centers

2016Q2
Declines in the Abuse of Extended Release Morphine Tablets and Capsules Following the Reformulation of OxyContin®

2016Q3
Comparing Prescription Opioids, Methadone, and Heroin Rates from the Treatment Episode Data Set to the RADARS® System Treatment Center Programs

2016Q4
Comparison of Population Rates between the Drug Abuse Warning Network (DAWN) and the RADARS® System Poison Center Program

2015Q1
Comparative Rates of Mortality and Severe Medical Effect Among Commonly Prescribed Opioid Analgesics: Calls to US Poison Centers Reporting Opioid Overdose Due to Intentional Abuse and Misuse Exposures

2015Q2
Reduced Street Price and Quantity Discounts for Diverted Extended Release OxyContin ER and Opana ER Following Crush Resistant Reformulation

2015Q3
Abuse Prevalence and Preference of Immediate Release versus Extended Release Opioids

2015Q4
Number of Prescription Opioid Tablets/Capsules Ingested in Intentional Abuse Exposures Cases Reported to Poison Centers

2014Q1
Appearance of Canadian Oxycodone Extended Release Products in the United States

2014Q2
Choice of Denominator in the Calculation of Opioid Abuse Rates

2014Q3
Opioid-Related Mortality Rates Estimated Using National Vital Statistics System Data versus RADARS® Poison Center Program Data

2014Q4
Prescription Opioid Death Rates by Gender using Data from The RADARS® System Poison Center Program

2013Q1
Kentucky – Impact of Opioid Abuse Deterrent Policies

2013Q2
Comparison of Unique Recipients of Dispensed Drugs and Total Number of Prescriptions Filled in the Calculation of Abuse Rates

2013Q3
Comparison of Drug Diversion Street Price and StreetRx Programs

2013Q4
Impact of Tamper Resistant Formulations on Rates of Abuse of Schedule II Opioids

2012Q1
Fatalities and polysubstance use among prescription opioid abuse cases using the RADARS System Poison Center program

2012Q2
Use of unique recipients of dispensed drug (URDD) in assessing the burden of abuse, misuse, and diversion of prescription opioid products

2012Q3
Prescription Opioid Abuse and Misuse rates from RADARS® System are Highly Correlated with Rates from The Drug Abuse Warning Network (DAWN)

2012Q4-1
Age trends in the abuse of prescription opioids

2012Q4-2
A comparison of three measures of prescription opioid availability